ArticleFrontiers in genetics2019
Development of an Immune-Related Prognostic Signature in Breast Cancer.
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Tumor-infiltrating lymphocytes display prognostic signatures associated with chemotherapy response in TNBC patients.iScience · 2026Article
- Clinical significance and potential molecular mechanisms of SYT15 expression in lung adenocarcinoma.Scientific reports · 2025Article
- Keratin 80 serves as a potential biomarker in metastatic breast cancer.Discover oncology · 2025Article
- Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.Journal of cancer research and clinical oncology · 2024Article
- Article
- New Biomarkers Based on Dendritic Cells for Breast Cancer Treatment and Prognosis Diagnosis.International journal of molecular sciences · 2023Article
- Article
- A signature of immune-related genes correlating with clinical prognosis and immune microenvironment in sepsis.BMC bioinformatics · 2023Article
- The prognostic value and response to immunotherapy of immunogenic cell death-associated genes in breast cancer.Frontiers in oncology · 2023Article
- EIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer.Biomolecules · 2022Article
- Identification and validation of a novel 16-gene prognostic signature for patients with breast cancer.Scientific reports · 2022Article
- A CD8Journal of mammary gland biology and neoplasia · 2022Article
- Establishment and Analysis of an Individualized Immune-Related Gene Signature for the Prognosis of Gastric Cancer.Frontiers in surgery · 2022Article
- Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma.Cancer cell international · 2021Article
- Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer.BMC cancer · 2021Article
- Construction and Identification of a Novel 5-Gene Signature for Predicting the Prognosis in Breast Cancer.Frontiers in medicine · 2021Article
- Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients.Frontiers in oncology · 2021Article
- Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer.Frontiers in oncology · 2021Article
- A Tumor Suppressor Gene-Based Prognostic Classifier Predicts Prognosis, Tumor Immune Infiltration, and Small Molecule Compounds in Breast Cancer.Frontiers in genetics · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough increased early detection, diagnosis and treatment have improved the outcome of breast cancer patients, prognosis estimation still poses challenges due to the disease heterogeneity. Accumulating data indicated an evident correlation between tumor immune microenvironment and clinical outcomes.
objectiveTo construct an immune-related signature that can estimate disease prognosis and patient survival in breast cancer.
methodsGene expression profiles and clinical data of breast cancer patients were collected from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, which were further divided into a training set (n = 499), a testing set (n = 234) and a Meta-validation set (n = 519). In the training set, immune-related genes were recognized using combination of gene expression data and ESTIMATE algorithm-derived immune scores. An immune-related prognostic signature was generated with LASSO Cox regression analysis. The prognostic value of the signature was validated in the testing set and the Meta-validation set.
resultsA total of 991 immune-related genes were identified. Twelve genes with non-zero coefficients in LASSO analysis were used to construct an immune-related prognostic signature. The 12-gene signature significantly stratified patients into high and low immune risk groups in terms of overall survival independent of clinical and pathologic factors. The signature also significantly stratified overall survival in clinical defined groups, including stage I/II disease. Several biological processes, such as immune response, were enriched among genes in the immune-related signature. The percentage of M
conclusionWe developed a 12-gene prognostic signature, providing novel insights into the identification of breast cancer with a high risk of death and assessment of the possibility of immunotherapy incorporation in personalized breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.